Please assess the completion status of the following clinical trial:

Trial Title: A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Have BPH Lower Urinary Tract Symptoms (LUTS) based on the disease diagnostic criteria at 1st screening.~* Have a history of ED based on the disease diagnostic criteria at 1st screening.~* Have LUTS with a Total International Prostate Symptom Score (IPSS) greater than or equal to 13 at 2nd screening.~* Have bladder outlet obstruction as defined by a Peak Urine Flow Rate (Qmax) of greater than or equal to 4 to less than or equal to 15 milliliter (mL)/second (sec) (from a prevoid total bladder volume as assessed by ultrasound of greater than or equal to 150 to less than or equal to 550 mL and a minimum voided volume of 125 mL) at 2nd screening.~* Make at least 4 sexual intercourse attempts during the 4-weeks after 2nd screening as recorded in the Sexual Encounter Profile (SEP) diary.~* Are sexually active with an adult female partner, and expect to remain sexually active with the same adult female partner for the duration of the study.~* Agree not to use any other approved or experimental BPH, overactive bladder (OAB), or ED treatments as indicated in the protocol at any time during the study.~* Have not taken treatments indicated in the protocol prior to the 2nd screening.~Exclusion Criteria:~* Current treatment with nitrates.~* Prostate-specific antigen (PSA) greater than 10.0 nanogram (ng)/mL at 1st screening.~* PSA greater than or equal to 4.0 to less than or equal to 10.0 ng/mL at 1st screening if prostate malignancy has not been ruled out to the satisfaction of a urologist.~* Clinical evidence of prostate cancer.~* Bladder postvoid residual volume (PVR) greater than or equal to 300 mL by ultrasound determination at 1st screening.~* History or clinical evidence of certain pelvic, bladder, urinary tract, or urinary retention conditions described in the protocol.~* Lower urinary tract instrumentation (including prostate biopsy) within 30 days of 1st screening.~* Clinical evidence of severe hepatic impairment at 1st screening.~* Current neurologic disease or condition associated with neurogenic bladder (for example, Parkinson's disease or multiple sclerosis).~* History of significant renal insufficiency as defined by the protocol.~* History of ED caused by other primary sexual disorders including premature ejaculation or ED caused by untreated endocrine disease.~* Presence of penile deformity judged by the investigator to be clinically significant.~* History of certain cardiac or cardiovascular conditions described in the protocol.~* History of resuscitated cardiac arrest.~* Current treatment with certain medications described in the protocol.~* Scheduled or planned surgery (or any procedure requiring general, spinal, or epidural anesthesia) during the course of the study.~* History of significant central nervous system injuries (including stroke or spinal cord injury) within 6 months of 1st screening.~* Glycosylated hemoglobin (HbA1c) greater than 9% at 1st screening.~* Prior treatment with phosphodiesterase type 5 (PDE5) inhibitors judged by the investigator to be ineffective. However, if the investigator judges that a subject's lack of response to as-needed PDE5 inhibitors is the result of inadequate coordination between dosing and sexual activity with a treatment, the subject may be enrolled.

- Gender: MALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tadalafil 2.5 mg (Type: EXPERIMENTAL): None
- Tadalafil 5 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).